HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
3/17/2026
Impact: 70
Healthcare
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Zenas BioPharma (NASDAQ: ZBIO) and maintained a price target of $44 for the stock.
AI summary, not financial advice
Share: